Fennec Pharmaceuticals Inc.
Hedge Funds Holdings
Last updated:
Fennec Pharmaceuticals Inc.‘s stocks are currently a part of 29 hedge funds’ portfolios, which represents 11.08% of the total amount of its stocks outstanding. This makes up a total of 2.91M shares of Fennec Pharmaceuticals Inc.. Compared to the previous quarter, the number fell by -76.62% or -9.53M shares fewer. As for the holding position changes, 41.38% (12) of current hedge fund investors increased the number of shares held, 17.24% (5) of current holders sold a part of the shares held, and 13.79% (4) closed the holdings completely. 9 hedge funds are new holders of Fennec Pharmaceuticals Inc. stock in Q1 2023, it is 31.03% of total holders.
Hedge funds holding Fennec Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 43 |
|---|---|
| Q3 2018 | 46 |
| Q4 2018 | 44 |
| Q1 2019 | 45 |
| Q2 2019 | 26 |
| Q3 2019 | 22 |
| Q4 2019 | 28 |
| Q1 2020 | 25 |
| Q2 2020 | 55 |
| Q3 2020 | 51 |
| Q4 2020 | 50 |
| Q1 2021 | 49 |
| Q2 2021 | 37 |
| Q3 2021 | 31 |
| Q4 2021 | 26 |
| Q1 2022 | 26 |
| Q2 2022 | 26 |
| Q3 2022 | 30 |
| Q4 2022 | 43 |
| Q1 2023 | 29 |
Hedge funds changes in Fennec Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 27 | 7 | 3 | 4 | 2 |
|---|---|---|---|---|---|
| Q3 2018 | 6 | 17 | 9 | 3 | 11 |
| Q4 2018 | 7 | 13 | 11 | 9 | 4 |
| Q1 2019 | 4 | 16 | 10 | 3 | 12 |
| Q2 2019 | 3 | 5 | 12 | 20 | -14 |
| Q3 2019 | 6 | 6 | 4 | 10 | -4 |
| Q4 2019 | 9 | 6 | 9 | 3 | 1 |
| Q1 2020 | 6 | 5 | 7 | 8 | -1 |
| Q2 2020 | 34 | 16 | 4 | 3 | -2 |
| Q3 2020 | 9 | 14 | 17 | 13 | -2 |
| Q4 2020 | 8 | 19 | 12 | 8 | 3 |
| Q1 2021 | 5 | 12 | 20 | 6 | 6 |
| Q2 2021 | 11 | 6 | 15 | 23 | -18 |
| Q3 2021 | 3 | 6 | 12 | 9 | 1 |
| Q4 2021 | 5 | 9 | 7 | 9 | -4 |
| Q1 2022 | 3 | 4 | 9 | 3 | 7 |
| Q2 2022 | 2 | 3 | 7 | 3 | 11 |
| Q3 2022 | 8 | 3 | 9 | 4 | 6 |
| Q4 2022 | 19 | 9 | 7 | 4 | 4 |
| Q1 2023 | 9 | 12 | 5 | 4 | -1 |
Hedge funds changes in Fennec Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 115,000 | 0 |
| Q2 2020 | 273,000 | 273,000 |
| Q3 2020 | 204,000 | 65,000 |
| Q4 2020 | 12,000 | 0 |
| Q1 2021 | 1,118,000 | 0 |
| Q2 2021 | 356,000 | 0 |
| Q3 2021 | 157,000 | 494,000 |
| Q4 2021 | 194,000 | 158,000 |
| Q1 2022 | 461,000 | 118,000 |
| Q2 2022 | 727,000 | 723,000 |
| Q3 2022 | 2,966,000 | 5,193,000 |
| Q4 2022 | 3,092,840 | 232,520 |
| Q1 2023 | 87,523,000 | 4,000 |